Home  |  About us  |  Editorial board  |  Current issue  |  Archives  |  Submit article  |  Instructions  |  Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 1194Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
REVIEW ARTICLE
Year : 2017  |  Volume : 8  |  Issue : 2  |  Page : 68-72

Deriving meaningful insights from clinical trial and postmarketing safety data: Perspectives from India


1 Safety Aggregate Reporting and Analytics, Global Delivery Network, QuintilesIMS, Quintiles Research (India) Private Limited; Marketed Product Safety Services, Lifecycle Safety, QuintilesIMS, Quintiles Research () Private Limited, Bengaluru, Karnataka, India
2 Medical Services, Global Delivery Network, Lifecycle Safety, QuintilesIMS, Quintiles Research (India) Private Limited, Bengaluru, Karnataka, India

Correspondence Address:
Anand Harugeri
145/12, 5th Cross, 19th Main, 1st N Block, Rajajinagar, Bengaluru - 560 010, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2229-3485.203046

Rights and Permissions

Today, drug safety data collection in India is both manual and electronic with reporting of potential overlapping and duplicate data, which is likely incomplete for further review and analysis. Furthermore, standardized data collection and timelines are not aligned with international standards. Complete coverage of safety data from all sources throughout the life of the drug cannot be ensured. There is no requirement to submit periodic safety data in clinical trials to regulatory authority. There is clearly a lack of emphasis on deriving meaningful safety data insights for ensuring patient safety. Efforts toward the early detection of drug safety issues are minimal. There is no mandate to publicly disclose drug safety findings. Benefit-risk evaluation of investigational and marketed products cannot be assured merely through annual status reports and periodic safety update reports, respectively. Focused initiatives involving stakeholders from regulatory, health-care, and pharmaceutical industries are required to change the current situation and enable derivation of meaningful insights from safety data. Equal emphasis on assessing real-time safety of the drugs and protection of patients' rights, safety, and well-being is required. Periodic safety data reporting in clinical trials, proactive safety data collection related to potential safety concerns, electronic medical records, electronic expedited reporting, collection of targeted data from stakeholders, and standardized and harmonized data collection aligned to the International Council for Harmonization guidelines are required. The Central Drugs Standard Control Organization should implement requirements to submit Development Safety Update Reports, Periodic Benefit-Risk Evaluation Reports, and Risk Management Plans. Access to clinical trials and postmarketing safety data through central repository would enable researchers to explore the data for application in clinical practice.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed457    
    Printed12    
    Emailed0    
    PDF Downloaded44    
    Comments [Add]    

Recommend this journal